Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. de Braud F, et al. Among authors: basu s. J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. J Clin Oncol. 2023. PMID: 36947734 Clinical Trial.
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. Janku F, et al. Among authors: basu s. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039779 Clinical Trial.
The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019.
Santos JV, Padron-Monedero A, Bikbov B, Grad DA, Plass D, Mechili EA, Gazzelloni F, Fischer F, Sulo G, Ngwa CH, Noguer-Zambrano I, Peñalvo JL, Haagsma JA, Kissimova-Skarbek K, Monasta L, Ghith N, Sarmiento-Suarez R, Hrzic R, Haneef R, O'Caoimh R, Cuschieri S, Mondello S, Kabir Z; GBD 2019 EU State of Health Collaborators; Freitas A, Devleesschauwer B. Santos JV, et al. BMC Public Health. 2024 May 22;24(1):1374. doi: 10.1186/s12889-024-18529-3. BMC Public Health. 2024. PMID: 38778362 Free PMC article.
All lytic bone lesions are not osteomyelitis- Think of DIRA!
Thangaraj A, Basu S, Mahajan S, Rawat A, Jindal A, Suri D. Thangaraj A, et al. Among authors: basu s. Rheumatology (Oxford). 2024 May 22:keae298. doi: 10.1093/rheumatology/keae298. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38775647 No abstract available.
Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis.
Siddiqui BA, Palaskas NL, Basu S, Dai Y, He Z, Yadav SS, Allison JP, Sheth RA, Tummala S, Buja M, Bhattacharjee MB, Iliescu C, Rawther-Karedath A, Deswal A, Wang L, Sharma P, Subudhi SK. Siddiqui BA, et al. Among authors: basu s. Cancer Immunol Res. 2024 May 20. doi: 10.1158/2326-6066.CIR-24-0011. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38768394
5,512 results